Navigation Links
Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
Date:11/9/2008

is a recombinant adeno-associated viral (rAAV) vector that transfers the SERCA2a gene into heart muscle cells. MYDICAR is delivered in a single dose directly to the heart muscle during a short outpatient procedure, performed in a standard cardiac catheterization laboratory via a small incision in the upper leg.

"These data demonstrate the safety of MYDICAR, and the improvements in cardiac function and overall condition observed in some patients further validate our target and approach," said Krisztina M. Zsebo, Ph.D., Chief Executive Officer of Celladon. "Given these early encouraging results, we are excited to have been given clearance to move into phase 2 of our study to continue to evaluate the ability of MYDICAR to improve heart function in more patients."

CUPID, which is funded by Celladon, is a Phase 1/2 trial. The Phase 1 portion reported today is an open-label, sequential dose escalation study. The Phase 2 portion is a randomized, double-blind, placebo-controlled, parallel-group, dose ranging trial that compares the use of MYDICAR at two or three dose levels with placebo. CUPID is expected to enroll 46 patients with advanced heart failure at 15 U.S. medical centers.

Study Results

Data from the Phase I in advanced heart failure was presented, and demonstrated that MYDICAR had an acceptable safety profile in these first nine patients, as determined by study investigators and an independent safety committee. In addition, improvements from baseline to six months across a number of parameters important in assessing heart failure status were observed, including symptomatic (5 patients), functional (4 patients), biomarker (2 patients) and left ventricular function/remodeling (6 patients). Of the nine patients treated, two with low levels of pre-existing antibodies to the AAV vector did not show improvement in these parameters.

The data are consistent with safety established for other rAAV vectors, which has been demonstrated in cl
'/>"/>

SOURCE Celladon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
2. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
3. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
4. NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study
5. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
6. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
7. Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD
8. CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
9. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
10. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
11. Lutonix Inc. Announces $20 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... for the fourth quarter of 2013 on Monday, February 3, ... release after the close of trading. (Logo: ... call to discuss the operating highlights and financial results for ...
(Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC ... guide with accompanying instrumentation to place and insert the ... the soft tissue (e.g. ligament) repair or reconstruction as ... heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
(Date:1/14/2014)... VALHALLA, N.Y. , Jan. 14, 2014   Oligomerix, Inc. ... disease modifying therapeutics for Alzheimer,s disease (AD) and related ... headquarters to Valhalla, NY as ... additional laboratory space at New York Medical College. ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Mich., June 17 GeneGo, Inc., a leading,provider ... announced,today that they were awarded a Phase I ... of a platform for functional data analysis in,cancer. ... Boston on the project. The system, MetaMiner (Oncology) ...
... SYDNEY, Australia, June 16 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS; ... Limited to,manage and provide eligible patients worldwide with ... The program will allow patients who are unable ... are considered by their physician,to be suffering from ...
Cached Medicine Technology:GeneGo is Awarded NCI Grant for Development of Systems Biology Platform for Integrative Data Analysis in Cancer 2Pharmaxis Establishes Named Patient Program for Bronchitol 2
(Date:7/10/2014)... decades, health-conscious people around the globe have taken antioxidant ... was one of the paths to good health and ... of antioxidant supplements have repeatedly dashed the hopes of ... risk. Virtually all such trials have failed to ... in several trials antioxidant supplementation has been linked with ...
(Date:7/10/2014)... could prove useful in treating small cell lung cancer - ... the Cancer Research UK Manchester Institute, based at The University ... teamed up with experts at AstraZeneca, as part of a ... as AZD3965 - on small cell lung cancer cells. , ... , also helps identify which patients are most likely to ...
(Date:7/9/2014)... sudden, acute episodes of low back pain are not ... pressure, wind direction and precipitation. Findings published in ... American College of Rheumatology (ACR), indicate that the risk ... speed or wind gusts, but was not clinically significant. ... nearly everyone experiences low back pain at some point ...
(Date:7/9/2014)... After Susan Wakulich was told she had an aneurysm, ... ahead of her. , "I was devastated," said Wakulich, who ... "I knew this was a serious diagnosis. Then I met ... that involved a less invasive procedure. It was something I ... participating in a multi-center U.S. clinical trial to evaluate the ...
(Date:7/9/2014)... the metabolism of stromal support cells and immune cells ... cell types in the development of diseases could ... cancer. That was the conclusion of a review article ... leading journal Nature . , Prof. Peter Carmeliet: ... The metabolism of cancer cells has been examined in ...
Breaking Medicine News(10 mins):Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Low back pain? Don't blame the weather 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Wake-up call for more research into cell metabolism 2
... difficile Inpatients on Any One Day; Patients,Dispersed Across ... The life-threatening,bacterium that causes diarrhea and more serious ... than previously,estimated, according to a new study released ... and Epidemiology (APIC)., "The National Prevalence Study ...
... web site by pilots, for pilots, www.wings4aviators.com , custom-embroiders U.S. ... To honor veterans, the company is donating 10% of the proceeds ... 501(c)(3) charity. , ... Hartland, WI (PRWEB) November 11, ...
... nursing, The Magnet Prize, was awarded to Abington Memorial Hospital (AMH) for ... Lake City, UT. This was the sixth year the award was ... ... the most prestigious awards in nursing, The Magnet Prize, was awarded to ...
... to helping seniors and their families understand their Medicare benefits ... hosting eight "Knowing Your Medicare Benefits for 2009" comparison presentations ... ... Torrance, CA (PRWEB) November 11, 2008 ...
... recognized as one of the top performing California physician groups by ... is one of only four California Physicians groups in the greater ... ... (PRWEB) November 11, 2008 -- This is the fifth straight year ...
... unveils TX11: a mobile computing cart designed to accommodate most laptop ... ... -- The Columbus, OH based medical product developer, Artromick, announced that ... mobile computing carts : the TX11 Medserver. While all Artromick ...
Cached Medicine News:Health News:Intestinal Infection Afflicts 13 of 1,000 Hospital Patients, Infection Rates 6.5 - 20 Times Greater Than Previous Estimates, New Study Says 2Health News:Intestinal Infection Afflicts 13 of 1,000 Hospital Patients, Infection Rates 6.5 - 20 Times Greater Than Previous Estimates, New Study Says 3Health News:New Web Site Offers Shirts with Custom-embroidered Aviator Wings for Veteran Military Pilots, Supports Families of the Wounded Fund 2Health News:New Web Site Offers Shirts with Custom-embroidered Aviator Wings for Veteran Military Pilots, Supports Families of the Wounded Fund 3Health News:New Web Site Offers Shirts with Custom-embroidered Aviator Wings for Veteran Military Pilots, Supports Families of the Wounded Fund 4Health News:Abington Memorial One of Just Six Hospitals in the U.S. to Win Magnet Prize 2Health News:Abington Memorial One of Just Six Hospitals in the U.S. to Win Magnet Prize 3Health News:Healthcare Partners Medical Group to Host Free Medicare Benefits Presentations 2Health News:Healthcare Partners Medical Group to Host Free Medicare Benefits Presentations 3Health News:Healthcare Partners Medical Group to Host Free Medicare Benefits Presentations 4Health News:HealthCare Partners Rated A 'Top Performing California Physician Group' By IHA For the Fifth Straight Year 2Health News:HealthCare Partners Rated A 'Top Performing California Physician Group' By IHA For the Fifth Straight Year 3Health News:Mobile Computing Carts Leader to Release New Clinical Computer Cart 2
Mac Pherson titanium tying forceps are ergonomic, very thin, angled with tying platforms. Round ergonomic design for great balance and feel. Fine platforms excellent for tying 10-0 suture....
Fine tying forceps, standard with smooth jaws. For 7-0 to 9-0 sutures....
Harms tying forceps, standard, straight with smooth jaws. For 7-0 to 9-0 sutures....
Tennant stainless steel tying forceps is extra delicate, straight with smooth jaws, 6 mm long platform, round handle with guide pin. For 9-0 to 11-0 sutures....
Medicine Products: